{
    "title": "Alphabet joins Eli Lilly, Novartis for AI drug discovery (NASDAQ:GOOG)",
    "date": "1/8/2024",
    "url": "https://seekingalpha.com/news/4053076-alphabet-joins-eli-lilly-novartis-ai-drug-discovery",
    "text": "Love Employee/iStock via Getty Images Isomorphic Labs, an AI-driven drug discovery firm operating under Google-parent Alphabet (NASDAQ:GOOG) (NASDAQ:GOOGL), has announced two separate research collaborations with Eli Lilly (NYSE:LLY) and Novartis (NYSE:NVS). The deal with Eli Lilly (LLY) marks its first pharmaceutical partnership, the London-based subsidiary of Alphabet (GOOGL) said in a press release Sunday. Per the terms, Isomorphic Labs will join LLY and NVS to discover small-molecule therapeutics against multiple targets. In return, it will receive $45M in cash upfront and up to $1.7B in performance-based milestone payments. The company is also eligible for tiered royalties of up to low-double digits on net sales. The deal with Novartis (OTCPK:NVSEF) will extend to three undisclosed targets and generate $37.5M upfront from the Swiss pharma giant, which has also agreed to fund certain research expenses. Isomorphic Labs will also receive up to $1.2B in performance-based milestone payments in addition to royalties on net sales ranging from mid-single up to low double-digit. "
}